Novo Nordisk announced that Ozempic (semaglutide injection) is now publicly listed in the province of Quebec under the Régie de L’assurance Maladie du Québec (RAMQ).
Ozempic is a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated alongside diet and exercise to improve glycemic control in adults with Type 2 diabetes when metformin is inappropriate. It can also be used with metformin, sulfonylurea and basal insulin with metformin.
This announcement follows the regulatory approval of Ozempic in January of 2018.
Ozempic was extensively studied in the SUSTAIN clinical trial program, which involved more than 8,000 adults with Type 2 diabetes. In the SUSTAIN program, Ozempic was studied in combination with oral antidiabetic agents and basal insulin.
“Having public access to effective treatment options is essential for people living with Type 2 diabetes,” said Dr. Jean-François Yale, senior scientist, department of medicine, division of endocrinology and metabolism at McGill University Health Centre (MUHC).
“When left uncontrolled, diabetes can cause serious health problems that can negatively impact a person’s quality of life,” Yale added. “Being able to prescribe Ozempic, which patients only need to take once a week, is an important step in helping to control the condition and reduce disease management risks.”
Vicky Chan, vice president, clinical development, medical and regulatory affairs, Novo Nordisk Canada added: “Type 2 diabetes impacts a person’s quality of life, and if blood glucose levels remain high, it can also be life-threatening.”
Chan said she believes that Ozempic has the potential to further improve the treatment of adults living with Type 2 diabetes and gives thanks to the Quebec government for their commitment to offering Canadians with Type 2 diabetes innovative treatment options.
Ozempic is available through many private insurance plans and publicly reimbursed through the following national and provincial government-sponsored drug benefit programs:
- Non-Insured Health Benefits Program
- Prince Edward Island
- Novo Nordisk Canada Inc. (2019, Nov. 14). OZEMPIC® is now listed on the Quebec provincial formulary for adults living with type 2 diabetes. PR Newswire. Retrieved Nov. 15, 2019, from https://prnmedia.prnewswire.com/news-releases/ozempic-r-is-now-listed-on-the-quebec-provincial-formulary-for-adults-living-with-type-2-diabetes-863568712.html